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Abstract
Background: Depression during pregnancy can have significant health consequences for the
mother and her infant. Antidepressant medications, which pass through the placenta, may increase
the risk of low birth weight and preterm delivery. The use of selective serotonin reuptake inhibitors
(SSRIs) during pregnancy may induce serotonergic symptoms in the infant after delivery.
Antidepressant medications in breast milk may also be passed to an infant. Vagus nerve stimulation
(VNS) therapy is an effective non-pharmacologic treatment for treatment-resistant depression
(TRD), but little information exists regarding the use of VNS therapy during pregnancy.
Case presentation: The patient began receiving VNS therapy for TRD in March 1999. The
therapy was effective, producing substantial reductions in depressive symptoms and improvement
of function. In 2002, the patient reported that she was pregnant. She continued receiving VNS
therapy throughout her pregnancy, labor, and delivery, which enabled the sustained remission of
her depression. The pregnancy was uneventful; a healthy daughter was delivered at full term.
Conclusion: In this case, VNS therapy provided effective treatment for TRD during pregnancy and
delivery. VNS was safe for the patient and her child.
Background
A pregnant patient with major depression requires effec-
tive management of depressive symptoms for her own
health and that of her child. Estimates of the prevalence of
depression among pregnant women vary widely, ranging
from 3.3% for major depression [1] to 20% for any type
of depression [2]. Rates of depression may be as high as
51% in selected populations [3]. These rates compare with
a 12-month worldwide prevalence of depression of 9.5%
in women [4]. Among pregnant women with depression,
many are untreated, sometimes discontinuing treatment
for depression after becoming pregnant [1,5].
Depression during pregnancy can have many serious con-
sequences. For the mother, depression is associated with
an overall decline in general health, physical and social
functioning, an increase in the experience of pain [3], and
obstetric complications [6-8]. Depression in late preg-
nancy is associated with post-partum depression [2],
while depression in early pregnancy increases the risk of
preeclampsia, a major complication characterized by rap-
idly progressive hypertension with proteinuria, edema, or
both [9]. For the infant, maternal depression during preg-
nancy was associated with admission to a neonatal inten-
sive care unit [7] and with spontaneous preterm delivery
in one study [10] but not in another [11].
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Because of the importance of managing depression during
pregnancy, numerous studies have examined the effects of
antidepressant medications on fetal and infant develop-
ment. Antidepressants and their metabolites pass through
the placenta [12] and increase the risk of low birth weight
[13,14] and preterm delivery [14,15]. Use of selective
serotonin reuptake inhibitors (SSRIs) by mothers during
pregnancy has been associated with substantially reduced
levels of platelet serotonin in newborns [16], which may
account for SSRI-induced serotonergic symptoms [17],
serotonin withdrawal syndrome[18], tremulousness,
reduced motor activity, heart rate variability [15], and
blunted pain response [19,20]. Increased dosing of SSRIs
may be required to maintain euthymia during later stages
of pregnancy [21], which may exacerbate some effects.
Antidepressants are transmitted to infants in breast milk,
where they usually have no discernible clinical effect.
However, in isolated reports, antidepressants in breast
milk have been associated with reduced feeding, somno-
lence, reduced growth, and possible seizure [22]. Because
both depression and its treatment with pharmacologic
interventions may pose risks to the patient and her child,
it is important to identify safe nonpharmacologic thera-
pies for that may be used to treat major depressive epi-
sodes during pregnancy.
Vagus nerve stimulation (VNS) therapy has been evalu-
ated for use in TRD [23-25]. A small pulse generator
implanted subcutaneously in the left thoracic area delivers
mild programmed pulses through an implanted lead to
the left vagus nerve in the neck. Approved for the treat-
ment of epilepsy since 1997, VNS therapy has been
administered to more than 32,000 patients worldwide
[26]. Several clinical studies have evaluated the use of
adjunctive VNS therapy in chronic or recurrent TRD.
In a 3-month open-label pilot study of patients with
chronic or recurrent TRD (bipolar or unipolar, defined by
Diagnostic and Statistical Manual of Mental Disorders,
4th Edition (DSM-IV) criteria [27], patients receiving
adjunctive VNS therapy exhibited statistically significant
improvements in average scores on the Hamilton 28-Item
Rating Scale for Depression (HRSD28), Montgomery
Asberg Depressive Rating Scale (MADRS), Global Assess-
ment of Function (GAF), and Clinical Global Impression
– Severity (CGI-S) scales [24]. After a year of follow-up,
adjunctive VNS therapy was associated with sustained
symptomatic benefit and sustained or enhanced func-
tional status [25].
Because pregnancy was a contraindication for enrollment
in the VNS studies of patients with TRD, there have been
no studies of the use of VNS therapy among pregnant
patients. A report of eight pregnancies in patients receiv-
ing VNS therapy for pharmacoresistent epilepsy has been
reported [28] concluded that VNS therapy does not pre-
vent conception and is not associated with any adverse
effects on the pregnancy or the neonate.
Case presentation
The study from which this case report was derived was
conducted in accordance with the ethical principles
defined in the Declaration of Helsinki of the World Med-
ical Association. The protocol was approved by the Insti-
tutional Review Boards (IRBs) of participating
institutions, and each patient provided written informed
consent.
The case study patient, a Caucasian woman aged 28 years
with a DSM-IV diagnosis of unipolar depression, was
enrolled in the acute and long-term phases of the pilot
study of VNS therapy for TRD. At acute-phase study entry,
she was noted to be obese and to have mild bronchocon-
striction, as well as hypertension, sleep apnea, and arthri-
tis in her knees, ankles, and feet. She reported that she had
suffered from recurring depression for 10 years, con-
founded by obesity, despite pharmacologic treatment and
psychotherapy. Her current depressive episode, which had
begun 22 months before study enrollment, was found to
be resistant to six different antidepressants (citalopram,
sertraline, venlafaxine, paroxetine, bupropion, and clon-
azepam) and the atypical antipsychotic risperidone. In the
year preceding enrollment in the study, she had been hos-
pitalized twice for depression. The patient's baseline phys-
ical and clinical characteristics are summarized in Table 1.
The VNS therapy device and leads were surgically
implanted on February 26, 1999. After recovery, the
Table 1: Baseline Physical and Clinical Characteristics of the 
Patient
Characteristic
Age 28 years
Height 168 cm
Weight 160 kg
Heart rate (BPM) 106
Blood pressure Systolic: 122
Diastolic: 88
Neurological examination Sad/depressed affect; other 
parameters within normal limits
Clinical assessment
HRSD28 49
MADRS 36
GAF 42
CGI-S 6
cm: centimeters; kg: kilograms; BPM: Beats per minute; HRSD28: 
Hamilton 28-Item Rating Scale for Depression; MADRS: 
Montgomery Asberg Depressive Rating Scale; GAF: Global 
Assessment of Function; CGI-S: Clinical Global Impression – SeverityAnnals of General Psychiatry 2005, 4:16 http://www.annals-general-psychiatry.com/content/4/1/16
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patient started receiving VNS therapy on March 17, 1999,
with the initial stimulation parameters set as shown in
Table 2. Substantial improvement was evident after 4
weeks, with depressive symptoms reduced and function-
ing improved as indicated by HRSD28, MADRS, CGI, and
GAF scores (Figures 1 through 3). After 11 months, her
HRSD28 score had decreased to 7 and her GAF score had
reached 96. The patient's VNS output current was reduced
to 0.25 milliamperes (mA) on August 31, 2001; other
stimulation parameters were unchanged.
With her depression in remission, the patient underwent
gastric bypass surgery for obesity on December 22, 2000.
The pulse generator was turned off on December 21, 2000
in preparation for her surgery; VNS therapy was resumed
on March 27, 2001. Twoyears after the surgery, she had
lost approximately 55 kg.
On May 30, 2002, the patient reported that she was preg-
nant with her first child. She was informed that, while
information was limited on the effects of VNS therapy
during pregnancy, no safety issues were known that would
affect the pregnancy. The patient decided to continue
receiving VNS therapy during the pregnancy; no changes
were made in stimulation parameters. In addition, she
continued to receive citalopram 80 mg per day and bupro-
pion 400 mg per day, after dosage reductions were consid-
ered and rejected by her physicians. She remained in
The patient experienced a substantial reduction in symptoms after receiving VNS therapy, as indicated by HRSD28 and MADRS  scores Figure 1
The patient experienced a substantial reduction in symptoms after receiving VNS therapy, as indicated by HRSD28 and MADRS 
scores. VNS therapy was initiated on March 17, 1999. The patient reported her pregnancy on May 30, 2002, and delivered a 
healthy child on January 24, 2003; remission of depression was sustained during the pregnancy.
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clinical remission of depression throughout her preg-
nancy (Figures 1 through 3). In compliance with the clin-
ical study protocol, the pregnancy was reported as a
serious adverse event that was not related to VNS therapy.
After an uneventful gestation period and normal sponta-
neous vaginal delivery with epidural anesthesia, the
patient delivered a healthy daughter at full term on Janu-
ary 24, 2003. The infant weighed 3.1 kg and was approxi-
mately 49 cm long.
VNS therapy was administered at the patient's normal set-
tings throughout labor and delivery. Contingency plans
had been made to discontinue stimulation if the patient
had required a Caesarian section procedure in which elec-
trocautery might be used. (To avoid damage to the pulse
generator and leads, the manufacturer recommends that
electrosurgery electrodes be placed as far as possible from
the implant, out of the direct path of current flow. Confir-
mation of correct programmed function of the device after
electrosurgery is also recommended.) However, the
patient did not require a Caesarian section, and pro-
grammed VNS therapy was continued during labor and
delivery.
The patient reported an episode of postpartum depression
lasting 11 days after delivery. She attributed the depressive
episode to difficulties in breast-feeding, and the episode
The patient's score on the CGI-S scale also indicated a substantial improvement after the initiation of VNS therapy Figure 2
The patient's score on the CGI-S scale also indicated a substantial improvement after the initiation of VNS therapy. Pregnancy 
from May 30, 2002 to January 24, 2003 did not significantly affect the patient's CGI scores.
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resolved without specific treatment. The child, now aged
approximately two years, exhibits normal age-appropriate
development.
Another serious adverse event, which was not considered
to be associated with VNS therapy, occurred after implant:
an episode of thrombophlebitis that resolved with medi-
cal therapy. Mild adverse events that the study investigator
considered possibly or definitely related to the implant
procedure or to VNS therapy were one episode each of
moderate leg pain, discomfort in the lower incisors during
stimulation, dizziness that resulted in a fall, and surgical
wound opening. The patient also experienced periodic
hoarseness, a common side effect associated with VNS
therapy that is considered tolerable by most patients. No
adverse events associated with the VNS therapy occurred
during pregnancy, labor, or delivery.
Conclusion
Management of pregnancy in a woman with depression
requires careful monitoring and treatment of depressive
symptoms in addition to other aspects of the patient's
condition. This patient, who had severe depression,
experienced sustained remission of her TRD during preg-
nancy while receiving VNS therapy in combination with
citalopram 80 mg per day and bupropion 400 mg per day.
In this case, VNS therapy provided effective adjunctive
Improvement in functioning is demonstrated by increases in GAF scores, beginning shortly after the start of VNS therapy and  continuing through her pregnancy and delivery Figure 3
Improvement in functioning is demonstrated by increases in GAF scores, beginning shortly after the start of VNS therapy and 
continuing through her pregnancy and delivery.
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treatment for the patient's depression during pregnancy
and delivery; VNS was safe for the patient and her child.
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